ORIGINAL ARTICLES   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3):198-206

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancre-atic carcinoma

Li S. ¹, Peck-Radosavljevic M. ², Kienast O. ¹, Preitfellner J. ¹, Havlik E. ³, Schima W. ⁴, Traub-Weidinger T. ¹, Graf S. ⁵, Beheshti M. ¹, Schmid M. ², Angelberger P. ⁶, Dudczak R. ¹

¹ Department of Nuclear Medicine Medical University of Vienna, Vienna, Austria 2 Department of Internal Medicine IV Division of Gastroenterology and Hepatology Medical University of Vienna, Vienna, Austria 3 Institute for Biomedical Technology and Physik Medical University of Vienna, Vienna, Austria 4 Department of Radiology, Medical University of Vienna, Vienna, Austria 5 Department of Internal Medicine II, Division of Cardiology Medical University of Vienna, Vienna, Austria, 6 Austrian Research Center, Seibersdorf, Austria

Aim. Imaging ­with radio­lab­elled vas­cu­lar endo­the­lial ­growth fac­tor (­VEGF) has ­been devel­oped for the local­isa­tion and diag­no­sis of a varie­ty of ­human sol­id ­tumors includ­ing gas­troin­tes­ti­nal ­tumors.
Methods. In ­this ­study we inves­ti­gat­ed the bio­dis­tri-
b­u­tion, safe­ty and ­absorbed ­dose of ­iodine-123 radio­lab­elled ­VEGF165 (123I-­VEGF165) in 9 ­patients ­with pan­creat­ic car­ci­no­ma. Following intra­ve­nous admin­is­tra­tion of 123I-­VEGF165 (189±17 MBq; <130 ­pmole (<5 μg) ­VEGF165 per ­patient), sequen­tial imag­es ­were record­ed dur­ing the ­initial 30 min ­PI. Serial ­whole-­body imag­es ­were ­acquired in ante­ri­or and pos­te­ri­or ­views at var­i­ous ­time ­points. All ­patients under­went sin­gle-pho­ton emis­sion tomog­ra­phy (­SPET) imag­ing. Dosimetry cal­cu­la­tions ­were per­formed on the ­basis of γ cam­e­ra ­data. Estimates of radi­a­tion ­absorbed ­dose ­were cal­cu­lat­ed ­using the MIR­DOSE 3 pro­gram.
Results. The high­est ­absorbed ­organ dos­es ­were ­found to be thy­roid (0.058±0.004 mGy/MBq), ­spleen (0.046± 0.017 mGy/MBq), uri­nary blad­der (0.04±0.02 mGy/MBq), ­lungs (0.034±0.009 mGy/MBq) and kid­neys (0.033±0.005 mGy/MBq). The effec­tive ­dose was esti­mat­ed to be 0.017±0.002 mSv/MBq. A major­ity of pri­mary pan­creat­ic ­tumors and ­their metas­ta­ses ­were vis­u­al­ized by 123I-­VEGF165 ­scan.
Conclusion. In ­vitro bind­ing ­results con­firmed spe­cif­ic bind­ing of 123I-­VEGF165 to pan­creat­ic ­tumor ­cells and tis­sues. 123I-­VEGF165 ­shows favor­able dosim­e­try and is a ­safe radio­phar­ma­ceu­ti­cal ­that may be of poten­tial val­ue for the imag­ing of ­VEGF recep­tor stat­us in ­vivo.